CSO Dr. Jake Micallef to Provide Update on Recent Company Milestones
NAMUR, Belgium, Aug. 3, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that its Chief Scientific Officer, Dr. Jake Micallef, is scheduled to present at the Wedbush PacGrow Healthcare Conference, being held August 11-12, 2015 at the Le Parker Meridien Hotel in New York, NY.
Dr. Micallef will present on Wednesday, August 12 at 10:55 a.m. EDT. During his presentation, he will discuss recent milestones achieved by the Company, including partnering with two consulting agencies to support market access of its NuQ® colorectal cancer tests in Europe, engaging a specialty clinical research organization to support initial entry of NuQ® colorectal cancer tests via U.S. CLIA labs, and expanding its Scientific Advisory Board. Dr. Micallef will also outline the science behind VolitionRx's Nucleosomics® technology platform and how its NuQ® tests have the potential to revolutionize detection of cancer through non-invasive, accurate, cost-effective and scalable cancer blood-based diagnostics.
The presentation will be webcast live at http://wsw.com/webcast/wedbush30/vnrx/ and available for at least 90 days after the event on Volition Rx's website at http://www.volitionrx.com/news/events-calendar.
Details of the presentation are as follows:
Wedbush PacGrow Healthcare Conference
Wednesday, August 12, 2015
10:55 a.m. EDT
Investors attending the conferences who would like to schedule a 1-on-1 meeting with VolitionRx management during the conference may do so by contacting Lee Roth or Joseph Green of The Ruth Group at email@example.com or firstname.lastname@example.org.
Further information about the Wedbush PacGrow Life Sciences Management Access Conference is available at https://www.wedbush.com/services/cmg/equities-division/mgmt-access-events.
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Anita Heward, VolitionRx
Telephone: +44 (0) 7756 034243
Kirsten Thomas, The Ruth Group
Telephone: +1 (646) 536-7014
Scott Powell, VolitionRx
Telephone: +1 (646) 650-1351
Lee Roth, The Ruth Group
Telephone: +1 (646) 536-7012
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this prospectus are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-to-present-at-wedbush-pacgrow-healthcare-conference-300122376.html
SOURCE VolitionRx Ltd